Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Berettyoujfalu – page 13

650 clinical trials in Berettyoujfalu, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Berettyoujfalu at a glance
650
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

650 trials in Berettyoujfalu

Open in trial search

Study on Ferric Derisomaltose for Patients with Iron Deficiency and Chronic Heart Failure

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ferric Derisomaltose
  • Sponsor:Pharmacosmos A/S

Graves' disease

Recruiting

Study on the Effectiveness and Safety of IMVT-1402 for Adults with Graves' Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Study comparing NVL-655 to alectinib in untreated patients with ALK-positive advanced non-small cell lung cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:NVL-655
  • Sponsor:Nuvalent Inc.

Study Comparing Oral Azacitidine and Cedazuridine with Subcutaneous Azacitidine for Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Taiho Oncology Inc.

Study of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:Astrazeneca AB

Bladder cancer

Recruiting

Study of mRNA-4157 and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Gastric cancer+3

Recruiting

Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Shanghai Henlius Biotech Inc.

Study on the Effectiveness of Lisaftoclax and Azacitidine in Adults with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ascentage Pharma Group Inc.

Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Anaemia+1

Recruiting

Study of Elritercept for Treating Anemia in Adults with Low to Intermediate Risk Myelodysplastic Syndromes

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Psychotic disorder+1

Recruiting

Study of trospium chloride and xanomeline tartrate (KarXT) in patients with psychosis associated with Alzheimer's disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Lupus nephritis

Recruiting

Study on the Effects and Safety of Ianalumab in Adults with Lupus Nephritis Who Completed Previous Treatment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Berettyoujfalu

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical trials focusing on primary prevention of atherosclerotic cardiovascular disease (ASCVD). The research examines advanced therapeutic approaches for reducing major adverse cardiovascular events in high-risk patients.

  • Cardiovascular Event Prevention
  • High-Risk Patient Management
  • Atherosclerosis Prevention

This groundbreaking research aims to evaluate new therapeutic strategies for improving cardiovascular outcomes in preventive cardiology, particularly focusing on patients who haven't yet experienced a cardiovascular event.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.